Skip to main content
. 2013 Mar 27;33(13):5553–5563. doi: 10.1523/JNEUROSCI.4409-12.2013

Figure 2.

Figure 2.

Validation of the AD neurodegenerative biomarkers. Distribution of the neurodegenerative biomarkers in the derivation (ADNI NC [blue], ADNI AD [orange]) and validation (BAC NC [black], UCSF AD [red]) samples. A, The multimodality biomarker was reduced for AD patients compared with normal controls (NC) across samples. The gray line denotes the discriminant cutoff score (values ≤0 indicate AD classification). B–D, The single-modality biomarkers, i.e., cortical thickness (B), FDG PET (C), intracranial volume-adjusted hippocampal volume (HVicv) (D), showed prominent reductions for AD patients across samples. Error bar plots display group-means and SD for each biomarker; the gray circles indicate individual data points.